Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)

Figure 1

Scheme of the METEOR trial. Patients meeting the inclusion criteria will be 1:1 randomized to 24 weeks of letrozole plus metformin or letrozole plus placebo. Core needle biopsies will be recommended after 4 weeks of treatment. Surgery will be performed within 2 weeks after the end of the 24 week treatment period.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us